Sanam Loghavi, MD

Articles by Sanam Loghavi, MD

Defining Advances in the WHO Classification for AML

December 8th 2023

The required blast threshold of 20% has now been omitted from AML with defining genetic abnormalities with the exception of AML with BCR::ABL1 and AML with CEBPA mutation.

Latest Updated Articles

Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL

Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC

JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update

LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors

Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma